ArticleJournal of thoracic disease2025
Convalescent plasma therapy for COVID-19 in patients with nasal catheter oxygen therapy.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Numerous studies have demonstrated that convalescent plasma therapy reduces mortality in coronavirus disease 2019 (COVID-19) patients. Current guidelines recommend nasal catheter oxygen therapy for most hypoxic patients during the early stages of the illness. However, limited data are available regarding the efficacy of convalescent plasma therapy in patients already receiving oxygen therapy. Given the widespread use of nasal catheter oxygen therapy in hypoxic COVID-19 patients and the increasing evidence supporting the efficacy of convalescent plasma, this study aimed to evaluate the efficacy and safety of convalescent plasma therapy in COVID-19 patients who were receiving early oxygen therapy. Methods: A retrospective study was conducted at the First Affiliated Hospital of Ningbo University, analyzing 112 COVID-19 patients treated with convalescent plasma from December 2022 to July 2023. Data on demographics, laboratory tests, and plasma doses were collected before and after convalescent plasma transfusion, alongside standard care. The primary outcome was 28-day mortality, with laboratory parameters as secondary outcomes. Results: On day 28, the mortality rate was 20% in the convalescent plasma group compared to 44% in the standard-care group (P=0.008). In severe COVID-19 cases, mortality was 34% in the convalescent plasma group versus 59% in the standard-care group (P=0.04). Among patients who received nasal catheter oxygen therapy for 48 hours or longer, mortality was 21% in the convalescent plasma group compared to 42% in the standard-care group (P=0.02). Conclusions: Convalescent plasma therapy administered to COVID-19 patients receiving nasal catheter oxygen therapy significantly reduced mortality at day 28.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.